Skip to main content
Premium Trial:

Request an Annual Quote

Innate Pharma Treats First CD20-Positive Lymphoma Patient in IPH6501 Trial

NEW YORK – Innate Pharma said Wednesday that it has treated the first lymphoma patient with IPH6501 in its Phase I/II clinical trial.

Through the study, Innate is evaluating IPH6501, a CD20-targeting tetraspecific natural killer cell engager, as a treatment for patients with advanced, relapsed, or refractory CD20-expressing B-cell non-Hodgkin lymphomas.

Marseille, France-based Innate has dubbed the treatment type an Anket, or antibody-based NK cell engager therapeutic. It is designed to co-engage the CD20 antigen on B cells as well as three receptors on patients' NK cells. These receptors include NKp46, CD16, and interleukin-2.

Innate expects to enroll up to 184 patients in the multicenter clinical trial, all of whom will need to have documented CD20-positive cancers to be eligible. The trial will include patients with diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma, among other eligible non-Hodgkin lymphoma subtypes.

As a primary goal of the trial, Innate will be assessing the treatment's safety and maximum tolerated dose. The firm will also evaluate preliminary efficacy endpoints such as overall response rate, duration of response, and progression-free survival.

"With the addition of the IL-2 variant, our second-generation Anket molecules can deliver proliferation signals to NK cells, and thus enhance their effector functions against cancer cells," Innate Chief Medical Officer Sonia Quaratino said in a statement. "Thanks to this novel format, IPH6501 represents a promising alternative strategy to T-cell therapies for patients with B-cell non-Hodgkin lymphomas."